CSF1R tyrosine kinase inhibitors (TKI) and antibodies yield response rates and tumor control in patients with diffuse type tenosynovial giant cell tumors (dTGCT). The gene discussed is CSF1R; the disease is tenosynovial giant cell tumor, diffuse type.